News

ASKLEP Inc. (Headquarters: 3-1-3 Higashi Ikebukuro, Toshima-ku, Tokyo, Japan, Representative Director and President: Hiroshi Ichikawa) establishes "ASKLEP TAIWAN Inc." to expand its drug development contract research organization (CRO) business.

Along with the globalization of drug development, we have been expanding overseas through the establishment of a subsidiary in China (ASKLEP CHINA Inc.) and forming partnerships with CROs in Europe, USA and Asia. Recently, clinical trials in Asia have been very active, with many business acquisitions taking place in Japan, China, Korea and Taiwan. Additionally, due to government-led improvements in the environment in which clinical trials are conducted, there has been an observed increase in Taiwan’s participation in clinical trials conducted in Asia.

Our aim is to increase the number of contracts for conducting clinical trials in East Asia by establishing a subsidiary in Taiwan and utilizing the resources of ASKLEP and ASKLEP CHINA. Regarding management of the Taiwan subsidiary, we will expand the business by utilizing management talent consisting of local personnel, making use of local networks.

About ASKLEP TAIWAN